Molecularly targeted therapies for recurrent glioblastoma: Current and future targets

Neurosurgical Focus

Volumn 37, Issue 6, 2014, Pages

  Lau, Darryl ^a   Magill, Stephen T ^a   Aghi, Manish K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Combination treatment; Glioblastoma; Molecular therapy; Overall survival; Progression free survival; Recurrent

Indexed keywords

BRAIN NEOPLASMS; GENETICS; GLIOBLASTOMA; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; PROCEDURES;

BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL;

EID: 84916933523     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2014.9.FOCUS14519     Document Type: Article

References (122)

1. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, et al: Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28:2817-2823, 2010
2. Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, et al: Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31:3212-3218, 2013
3. Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC, et al: Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 49:380-390, 2001
4. Brandes AA, Ermani M, Turazzi S, Scelzi E, Berti F, Amistà P, et al: Procarbazine and high-dose tamoxifen as a secondline regimen in recurrent high-grade gliomas: a phase II study. J Clin Oncol 17:645-650, 1999
5. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al: A perivascular niche for brain tumor stem cells. Cancer Cell 11:69-82, 2007
6. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068, 2008
7. Carbonell WS, DeLay M, Jahangiri A, Park CC, Aghi MK: b1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res 73:3145-3154, 2013
8. Chamberlain MC, Johnston SK: Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol 96:259-269, 2010
9. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, et al: Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23:357-361, 2005
10. Chatterjee S, Matsumura A, Schradermeier J, Gillespie GY: Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents. J Neurooncol 46:135-144, 2000
11. Chen Y, Wang M, Zhong W, Zhao J: Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. Lung Cancer 82:313-318, 2013
12. Chi A, Norden AD, Wen PY: Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther 7:1537-1560, 2007
13. Chow LQ, Eckhardt SG: Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884-896, 2007
14. Clarke ID, Dirks PB: A human brain tumor-derived PDGFRalpha deletion mutant is transforming. Oncogene 22:722-733, 2003
15. Cloughesy TF, Cavenee WK, Mischel PS: Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol 9:1-25, 2014
16. Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, et al: Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 24:3651-3656, 2006
17. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, et al: Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5:e8, 2008
18. Couldwell WT, Antel JP, Yong VW: Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein kinase C. Neurosurgery 31:717-724, 1992
19. Couldwell WT, Hinton DR, Surnock AA, DeGiorgio CM, Weiner LP, Apuzzo ML, et al: Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 2:619-622, 1996
20. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC: PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15:1913-1925, 2001
21. de Boüard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, et al: Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 9:412-423, 2007
22. de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, et al: Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol 90:89-97, 2008
23. de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, et al: Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 29:2689-2695, 2011
24. Deeken JF, Löscher W: The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 13:1663-1674, 2007
25. Deng Y, Feng W, Wu J, Chen Z, Tang Y, Zhang H, et al: The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer. Mol Clin Oncol 2:116-120, 2014
26. Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE II, Bailey L, et al: Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118:1302-1312, 2012
27. Di Cristofori A, Carrabba G, Lanfranchi G, Menghetti C, Rampini P, Caroli M: Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma. Anticancer Res 33:3383-3389, 2013
28. Doherty L, Gigas DC, Kesari S, Drappatz J, Kim R, Zimmerman J, et al: Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67:156-158, 2006
29. Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11-22, 2003
30. Dresemann G: Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 16:1702-1708, 2005
31. Dresemann G, Weller M, Rosenthal MA, Wedding U, Wagner W, Engel E, et al: Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol 96:393-402, 2010
32. Ekstrand AJ, Sugawa N, James CD, Collins VP: Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A 89:4309-4313, 1992
33. Eller JL, Longo SL, Hicklin DJ, Canute GW: Activity of antiepidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery 51:1005-1014, 2002
34. Feldkamp MM, Lau N, Guha A: Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and antiangiogenic effects. Oncogene 18:7514-7526, 1999
35. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 9:669-676, 2003
36. Ferrara N, Hillan KJ, Novotny W: Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333:328-335, 2005
37. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS: Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67:3560-3564, 2007
38. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1990
39. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, et al: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391-400, 2005
40. Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F, et al: Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. NeuroOncol 14:215-221, 2012
41. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740, 2009
42. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, et al: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23:5294-5304, 2005
43. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, et al: Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27:2052-2058, 2009
44. Gately S: The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 19:19-27, 2000
45. Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, et al: Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol 106:147-153, 2012
46. Gilbertson RJ, Rich JN: Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 7:733-736, 2007
47. Hainsworth JD, Shih KC, Shepard GC, Tillinghast GW, Brinker BT, Spigel DR: Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/ everolimus as first-line treatment for patients with glioblastoma. Clin Adv Hematol Oncol 10:240-246, 2012
48. Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, et al: Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 12:508-516, 2010
49. Hegi ME, Diserens AC, Bady P, Kamoshima Y, Kouwenhoven MC, Delorenzi M, et al: Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib-a phase II trial. Mol Cancer Ther 10:1102-1112, 2011
50. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, et al: Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52:3213-3219, 1992
51. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027, 2005
52. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432, 2003
53. Jahangiri A, Aghi MK, Carbonell WS: ß1 integrin: critical path to antiangiogenic therapy resistance and beyond. Cancer Res 74:3-7, 2014
54. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987-989, 2001
55. Johnson DR, O'Neill BP: Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 107:359-364, 2012
56. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428, 2002
57. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, et al: Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12:7271-7278, 2006
58. Kast RE, Boockvar JA, Brüning A, Cappello F, Chang WW, Cvek B, et al: A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget 4:502-530, 2013
59. Kerbel RS: Tumor angiogenesis. N Engl J Med 358:2039-2049, 2008
60. Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, et al: Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol 25:3137-3143, 2007
61. Kreisl TN, Lassman AB, Mischel PS, Rosen N, Scher HI, Teruya-Feldstein J, et al: A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol 92:99-105, 2009
62. Kreisl TN, Smith P, Sul J, Salgado C, Iwamoto FM, Shih JH, et al: Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol 111:41-48, 2013
63. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190-198, 2001
64. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, et al: SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60:4152-4160, 2000
65. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA: Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62:3729-3735, 2002
66. Lv S, Teugels E, Sadones J, De Brakeleer S, Duerinck J, Du Four S, et al: Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. Int J Oncol 41:1029-1035, 2012
67. Millward MJ, Cantwell BM, Lien EA, Carmichael J, Harris AL: Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur J Cancer 28A:805-810, 1992
68. Montgomery RB, Moscatello DK, Wong AJ, Cooper JA, Stahl WL: Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor. J Biol Chem 270:30562-30566, 1995
69. Nam DH, Park K, Suh YL, Kim JH: Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. Oncol Rep 11:863-869, 2004
70. Neyns B, Sadones J, Joosens E, Bouttens F, Verbeke L, Baurain JF, et al: Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol 20:1596-1603, 2009
71. Nonnenmacher L, Westhoff MA, Fulda S, Karpel-Massler G, Halatsch ME, Engelke J, et al: RIST: A potent new combination therapy for glioblastoma. Int J Cancer [epub ahead of print], 2014
72. Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, et al: Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol 15:930-935, 2013
73. Peereboom DM, Ahluwalia MS, Ye X, Supko JG, Hilderbrand SL, Phuphanich S, et al: NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol 15:490-496, 2013
74. Pietras K, Ostman A, Sjöquist M, Buchdunger E, Reed RK, Heldin CH, et al: Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61:2929-2934, 2001
75. Pietras K, Rubin K, Sjöblom T, Buchdunger E, Sjöquist M, Heldin CH, et al: Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62:5476-5484, 2002
76. Plate KH, Breier G, Farrell CL, Risau W: Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab Invest 67:529-534, 1992
77. Polivka J Jr, Polivka J, Rohan V, Topolcan O, Ferda J: New molecularly targeted therapies for glioblastoma multiforme. Anticancer Res 32:2935-2946, 2012
78. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick FT Jr: Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res 50:7134-7138, 1990
79. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, et al: A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 12:95-103, 2010
80. Reardon DA, Desjardins A, Peters K, Gururangan S, Sampson J, Rich JN, et al: Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol 103:371-379, 2011
81. Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, et al: Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neurooncol 107:155-164, 2012
82. Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, et al: Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 117:5351-5358, 2011
83. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE II, et al: Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 96:219-230, 2010
84. Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, et al: Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer 101:1995-2004, 2009
85. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, et al: Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23:9359-9368, 2005 (Erratum in J Clin Oncol 24:1224, 2006)
86. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, et al: Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26:5610-5617, 2008
87. Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, Desjardins A, et al: Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 12:860-868, 2006
88. Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, et al: Effect of CYP3A-inducing antiepileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 101:57-66, 2011
89. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, et al: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133-142, 2004
90. Russell JS, Brady K, Burgan WE, Cerra MA, Oswald KA, Camphausen K, et al: Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 63:7377-7383, 2003
91. Salmaggi A, Eoli M, Frigerio S, Silvani A, Gelati M, Corsini E, et al: Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 62:297-303, 2003
92. Schmelzle T, Hall MN: TOR, a central controller of cell growth. Cell 103:253-262, 2000
93. Seystahl K, Weller M: Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma? Expert Opin Investig Drugs 21:605-617, 2012
94. Shih AH, Dai C, Hu X, Rosenblum MK, Koutcher JA, Holland EC: Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res 64:4783-4789, 2004
95. Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, et al: CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28:85-94, 2009
96. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, et al: Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287-290, 2007
97. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, et al: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375-1382, 2002
98. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, et al: Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28:2712-2718, 2010
99. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
100. Sun CC, Qu XJ, Gao ZH: Integrins: players in cancer progression and targets in cancer therapy. Anticancer Drugs 25:1107-1121, 2014
101. Takayama N, Sato N, O'Brien SG, Ikeda Y, Okamoto S: Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 119:106-108, 2002
102. Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, et al: Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer 130:223-233, 2012
103. Ugur HC, Ramakrishna N, Bello L, Menon LG, Kim SK, Black PM, et al: Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. J Neurooncol 83:267-275, 2007
104. Uhrbom L, Hesselager G, Nistér M, Westermark B: Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res 58:5275-5279, 1998
105. van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, et al: Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 27:1268-1274, 2009
106. van den Bent MJ, Taal W: Are we done with dose-intense temozolomide in recurrent glioblastoma? Neuro Oncol 16:1161-1163, 2014
107. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110, 2010
108. Vredenburgh JJ, Desjardins A, Herndon JE II, Marcello J, Reardon DA, Quinn JA, et al: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729, 2007
109. Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D, et al: Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57:4183-4186, 1997
110. Wang T, Agarwal S, Elmquist WF: Brain distribution of cediranib is limited by active efflux at the blood-brain barrier. J Pharmacol Exp Ther 341:386-395, 2012
111. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, et al: AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389-4400, 2005
112. Weis SM, Cheresh DA: Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437:497-504, 2005
113. Weller M, Cloughesy T, Perry JR, Wick W: Standards of care for treatment of recurrent glioblastoma-are we there yet? Neuro Oncol 15:4-27, 2013
114. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, et al: Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12:4899-4907, 2006
115. Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, et al: Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28:1168-1174, 2010
116. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129-3140, 2008
117. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, et al: Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 98:2018-2026, 1996
118. Xue Y, Lim S, Yang Y, Wang Z, Jensen LD, Hedlund EM, et al: PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med 18:100-110, 2012
119. Yin D, Ong JM, Hu J, Desmond JC, Kawamata N, Konda BM, et al: Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 13:1045-1052, 2007
120. Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, Gilbert MR, et al: Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol 12:1061-1070, 2010
121. Yust-Katz S, Liu D, Yuan Y, Liu V, Kang S, Groves M, et al: Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. Cancer 119:2747-2753, 2013
122. Zustovich F, Landi L, Lombardi G, Porta C, Galli L, Fontana A, et al: Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. Anticancer Res 33:3487-3494, 2013